

To  
The Manager (Listing)  
BSE Limited  
Phiroz Jeejeebhoy Towers,  
Dalal Street, Fort Mumbai-400001

Date: 14.08.2025

Scrip Code: 530313 [KIMIABL]

**Sub: Outcome of Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015.**

Dear Sir/Ma'am,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations") read with Para A of Part A of Schedule III to the said Regulations, we wish to inform you that the Board of Directors in their meeting held today i.e., on Thursday, August 14, 2025 which commenced at 12:00 P.M. and concluded at 02:30 PM and the following businesses, amongst others, were transacted:

- 1) Approval of Unaudited financial results, on standalone basis, of the company for the quarter and three months ended June 30, 2025 in accordance with the Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and taking on record the limited Review Report of the Auditors on the same (copy attached as **Annexure A**).
- 2) Noted and discussed the Warning letter dated July 25, 2025 received from BSE Limited ("BSE").
- 3) Approval for raising an Unsecured Loan of Rupees 2crores with an interest rate of 8% Per annum.
- 4) Appointment Mr. Pradip Kumar Sharma as the chief Financial Officer ("CFO") of the Company with immediate effect, the required details of the appointee are enclosed herewith as **Annexure B**.

The meeting of the Board commenced at 12:00 PM (IST) and concluded at 02:30 PM (IST).

The Unaudited Standalone Financial Results will be upload on the website of the Company at [www.kimiabiosciences.com](http://www.kimiabiosciences.com)

You are requested to take the same on record.

Thanking you,

For KIMIA BIOSCIENCES LIMITED

Digitally signed  
by Sameer Goel  
Date:  
2025.08.14  
14:30:22 +05'30'

**Sameer Goel**  
**Managing Director & Chief Executive Officer**  
**DIN:00161786**

**KIMIA BIOSCIENCES LIMITED**

Regd. Office/Works  
Village Bhondsi, Damdama Lake Road,  
Gurugram, Haryana-122102  
Tel.: +91 9654746544, 9654206544

Corporate Office  
974, 9<sup>th</sup> Floor, Aggarwal Millennium Tower-II  
Netaji Subhash Place, Pitampura, New Delhi-110034, INDIA  
Tel.: +91 11 47063600, 470630601

**KIMIA BIOSCIENCES LIMITED**

Regd. Office : Village Bhondsi, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102

Phone: +91 9654746544, 9654206544 Email: compliance.kimia@gmail.com &amp; info@kimiabiosciences.com

Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025**

S. No	Particulars	Quarter ended			Year Ended
		30-06-2025	31-03-2025	30-06-2024	31-03-2025
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
I	Revenue from Operations	2,358.41	3,824.38	2,239.93	11,892.08
II	Other Income	84.69	44.20	8.33	132.03
III	<b>Total Income (I+II)</b>	<b>2,443.10</b>	<b>3,868.58</b>	<b>2,248.26</b>	<b>12,024.11</b>
IV	<b>Expenses:</b>				
	a) Cost of materials consumed	1,706.19	2,892.82	1,497.22	7,455.02
	b) Change in inventories of finished goods and work-in-prog	(290.32)	(449.82)	(274.57)	(368.23)
	c) Employee benefits expenses	327.67	278.56	342.83	1,367.89
	d) Finance costs	174.71	140.16	110.84	455.70
	e) Depreciation and amortisation expense	93.53	87.90	89.78	337.89
	f) Other expenses	362.18	284.78	303.96	1,412.42
V	<b>Total Expenses (IV)</b>	<b>2,373.96</b>	<b>3,234.40</b>	<b>2,070.06</b>	<b>10,660.69</b>
VI	<b>Profit/(loss) before exceptional items and Tax (III-V)</b>	<b>69.14</b>	<b>634.18</b>	<b>178.20</b>	<b>1,363.42</b>
VII	Exceptional Items	-	-	-	-
VI	<b>Profit/(loss) before tax (IV-V)</b>	<b>69.14</b>	<b>634.18</b>	<b>178.20</b>	<b>1,363.42</b>
VII	<b>Tax expenses:</b>				
	a) Current Tax	-	-	29.74	-
	b) Deferred Tax charge / (credit)	8.74	435.01	4.75	402.18
VIII	<b>Profit/(loss) for the period (VI-VII)</b>	<b>60.40</b>	<b>199.17</b>	<b>143.70</b>	<b>961.24</b>
IX	<b>Other Comprehensive Income</b>				
A.	Items that will not be reclassified to Profit or Loss (Net of				
	- Remeasurement of defined benefit plans	-	-	-	-
B.	Items that will be reclassified to Profit or Loss (Net of Tax)	-	-	-	-
X	<b>Total Comprehensive Income for the period (VIII+IX)</b>	<b>60.40</b>	<b>199.17</b>	<b>143.70</b>	<b>961.24</b>
XI	Paid up equity share capital (Face value of Rs. 1 per equity share)	473.13	473.13	473.13	473.13
XII	<b>Other Equity</b>				<b>523.48</b>
XIII	<b>Earnings per equity share (not annualised)</b>				
	Basic in Rs.	0.13	0.42	0.30	2.03
	Diluted in Rs.	0.13	0.42	0.30	2.03

**Other Notes**

- The business activity of the Company falls within a single primary business segment viz 'Pharmaceuticals' and hence there is no other reportable segment as per Ind AS 108 'operating segments'.
- The figures for three months ended June 30, 2025 are the balancing figure between audited figures in respect of the full financial year and published year to date figures up to the nine months of the previous financial year. The figures for the previous periods have been regrouped/ rearranged, wherever considered necessary, to confirm current period classifications.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 14, 2025.

Date : August 14, 2025

Place : New Delhi

FOR KIMIA BIOSCIENCES LIMITED



*Sameer Goel*  
 Sameer Goel  
 (Director)  
 DIN - 00161786



Review Report

To  
The Board of Directors  
Kimia Biosciences Limited  
Village Bhondsi, Tehsil Sohna  
Gurgaon Haryana-122102

1. We have reviewed the accompanying statement of unaudited financial results of Kimia Biosciences Limited (the "Company") for the quarter ended June 30, 2025 and year to date results for the period from April 01, 2025 to June 30, 2025 (the "Statement"), being submitted by the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulation, 2015"), which has been initialled by us for identification purposes.
2. The statement is the responsibility of the Company's Management which has been approved by the Board of Directors and prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in accordance with applicable accounting standards prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Neeraj Arora and Associates  
FRN 021309

Neeraj Kumar Arora  
M. No. 510750  
UDIN:- 25510750BMIEGQ8394  
Place:- Gurugram  
Dated:- August 14, 2025



## Annexure B

For appointment of Mr. Pradip Kumar Sharma, as Chief Financial Officer of the Company ("CFO").

Particulars/Requirements	Details
Reason for change i.e. Appointment/Re-Appointment	Appointment
Date of Appointment/Re-Appointment and terms of Appointment/Re- Appointment	With effect of 14.08.2025
Brief Profile	Mr.Pradip Sharma has over 10 years of experience in finance , accounting ,taxation and treasury management and corporate governance. He has held senior leadership position in several listed companies.
Disclosure of relationship of Directors inter-se	None

Thanking you,  
For KIMIA BIOSCIENCES LIMITED

Digitally signed  
by Sameer Goel  
Date:  
2025.08.14  
14:31:15 +05'30'

**Sameer Goel**  
**Managing Director & Chief Executive Officer**  
**DIN: 00161786**

### KIMIA BIOSCIENCES LIMITED

Regd. Office/Works  
 Village Bhondsi, Damdama Lake Road,  
 Gurugram, Haryana-122102  
 Tel.: +91 9654746544, 9654206544

Corporate Office  
 974, 9<sup>th</sup> Floor, Aggarwal Millennium Tower-II  
 Netaji Subhash Place, Pitampura, New Delhi-110034, INDIA  
 Tel.: +91 11 47063600, 470630601

LIST/COMP/HV/355/2025-26

July 25, 2025

Company Secretary  
**Kimia Biosciences Ltd**  
Village Bhondsi,  
Tehsil Sohna, Gurugram,  
Haryana, 122102

**Sub: Warning letter under 4(2)(e) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR').**

Dear Sir/Madam,


This is with reference to the submission made by the company under regulation 34 of SEBI LODR, for the financial year ended March 2024 i.e., Submission of Annual Report to Exchange. In same regards, it was observed that the Company had neither disclosed intimation for extension nor submitted extension letter of ROC Delhi to the Exchange.

In this regard, your immediate attention is drawn to **Regulation 4(2)(e)** of SEBI LODR regulations 2015, which emphasis on Disclosure and transparency "The listed entity shall ensure timely and accurate disclosure on all material matters including the financial situation, performance, ownership, and governance". In view of the above, the Company is hereby advised to be careful in future to avoid recurrence of such lapses and ensure exercise of due diligence and accuracy while submitting disclosures to the Stock Exchange.


You are advised to ensure that the Company files relevant, complete and adequate information regarding material events / incidents impacting the Company in compliance with the SEBI LODR not only in letter but in spirit. Filing incomplete information or delay in disclosing the details as required under the SEBI LODR in future would attract suitable disciplinary action, as may be deemed fit.

You are further advised to place this letter before the Company's Board of Directors in the upcoming board meeting and disseminate the letter to the Stock Exchange(s).

Yours faithfully,



**Manu Thomas**  
Deputy Vice President  
Listing Compliance



**Haşti Vora**  
Deputy Manager  
Listing Compliance